Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 42/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed with results

Key Signals

4 with results75% success

Data Visualizations

Phase Distribution

4Total
P 2 (2)
P 3 (1)
P 4 (1)

Trial Status

Completed3
Terminated1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT04677712Phase 4CompletedPrimary

Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite

NCT04170296Phase 3CompletedPrimary

Real World CCH Study in Adult Females With Cellulite

NCT04209530Phase 2Terminated

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

NCT01987986Phase 2CompletedPrimary

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

Showing all 4 trials

Research Network

Activity Timeline